Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Docetaxel + S-1 in Stage III Gastric Cancer
NCT04152889Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Countries
- 1
- Sponsor
- Renji Hospital
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- gastric cancer (GC)
01
Overview
Phase 2, open-label trial of camrelizumab in gastric cancer (GC), sponsored by Renji Hospital. Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Stage III gastric cancer patients with PD-L1 CPS >= 10%, MSI-H, EBV+, or dMMR status, no prior anti-tumor treatment.
04
Endpoints
Primary
Disease-Free Survival
Secondary
Overall Survival
Adverse Events
Beyond the preview
Go deeper on NCT04152889.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152889.